We continue to find new and innovative ways of collaborating with academic institutions, biotechs and pharmaceutical companies. By sharing knowledge and resources with other scientists, we collectively stand a much better chance of delivering effective treatments for serious diseases. We are interested in collaborating with research partners across all stages of drug discovery; from the initial idea through to early clinical development.
Our Open Innovation platform provides an open, collaborative approach to link our expertise, unique research tools, optimised molecules, technologies and challenges with your research capabilities and interests.
In August and September, we will be presenting the latest research in our three focus areas - Oncology, Respiratory and Cardiovascular and Metabolic Diseases.
The ESC Annual Congress 2017 will take place in Barcelona, Spain from 26-30 August 2017. The congress will be the world's largest cardiovascular congress with over 500 expert sessions and 11,000 abstracts.
The ESMO 2017 Congress will take place in Madrid, Spain from 8-12 September. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe.
The ERS International Congress 2017 will take place in Milan, Italy from 9-13 September. It is the largest meeting of respiratory professionals in the world.
The EASD Annual Meeting 2017 will take place in Lisbon, Portugal, from 11-15 September. EASD 2017 will be the largest international scientific meeting on diabetes and its comorbidities.
It’s amazing what you can achieve with the right science – when combined with technology at an industrialised scale we fuel the medicines discovery pipeline.
Paul Harper, Associate Principal Scientist, Discovery Sciences, IMED Biotech Unit
Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.
We have
projects in our pipeline
There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development
strategic science centres
Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries
At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.
Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.
We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.
I often say being in Business Development is having the best job in AstraZeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients.
Shaun Grady, Vice-President Business Development Operations
We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.
Our Open Innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development.
The best science doesn't happen in isolation.
2017 is set to be a defining year for the company as we bring new medicines to patients across the globe.
Pascal Soriot, Executive Director and Chief Executive Officer
Q1 2017 Results
Find all the latest dates for ex-dividends, investor roadshows and more
Find all the latest announcements from the stock exchange
Find out more about investing in AstraZeneca, everything from investor relations to dividend policies.
